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Abstract
A PI3Kα-selective inhibitor has recently been approved for use in breast tumors harboring
mutations in PIK3CA, the gene encoding p110α. Preclinical studies have suggested that the
PI3K/AKT/mTOR signaling pathway influences stemness, a dedifferentiation-related cellu-
lar phenotype associated with aggressive cancer. However, to date, no direct evidence for
such a correlation has been demonstrated in human tumors. In two independent human
breast cancer cohorts, encompassing nearly 3,000 tumor samples, transcriptional footprint-
based analysis uncovered a positive linear association between transcriptionally-inferred
PI3K/AKT/mTOR signaling scores and stemness scores. Unexpectedly, stratification of
tumors according to PIK3CA genotype revealed a “biphasic” relationship of mutant PIK3CA
allele dosage with these scores. Relative to tumor samples without PIK3CA mutations, the
presence of a single copy of a hotspot PIK3CA variant was associated with lower PI3K/AKT/
mTOR signaling and stemness scores, whereas the presence of multiple copies of PIK3CA
hotspot mutations correlated with higher PI3K/AKT/mTOR signaling and stemness scores.
This observation was recapitulated in a human cell model of heterozygous and homozygous
PIK3CAH1047R expression. Collectively, our analysis (1) provides evidence for a signaling
strength-dependent PI3K-stemness relationship in human breast cancer; (2) supports eval-
uation of the potential benefit of patient stratification based on a combination of conventional
PI3K pathway genetic information with transcriptomic indices of PI3K signaling activation.
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Author summary
Breast cancers often have increased activity of the so-called PI3Kα enzyme and the path-
way it activates, usually attributed to genetic alterations in the PIK3CA gene, encoding a
critical PI3Kα component. Recent cell studies have shown that effects of a PIK3CAmuta-
tion depend on how many copies are present. For example, two copies of a strong muta-
tion, but not one, fix cells in a state of “stemness”, a property associated with tumor
aggressiveness and therapy failure. To determine relationships among PI3K genetic varia-
tion, PI3K activity and stemness in breast cancers we used data from independent patient
cohorts encompassing nearly 3,000 tumors. Using PI3K signaling or stemness scores
derived from gene expression data, we found a strong, positive association between the
scores: aggressive tumors show the highest scores. In contrast, the relationship of these
scores with PIK3CAmutation status was unexpected–cancers with one PIK3CAmutant
copy showed a decrease in both scores, while they increased in cancers with additional
copies. This was confirmed in cellular models. This suggests that using binary information
about a PIK3CAmutation to define patient groups for trials may miss important effects of
allele dosage. We suggest that grouping may be improved by combining PIK3CAmuta-
tional information with functional indices of PI3K pathway activation.
Introduction
Activating mutations in PIK3CA are among the most common somatic point mutations in
cancer, together with inactivation or loss of the tumor suppressor PTEN, a negative regulator
of class I phosphoinositide 3-kinase (PI3K) enzymes [1–3]. PI3Kα-selective inhibitors are now
making good progress in the clinic [4], with the PI3Kα-specific inhibitor alpelisib (Piqray/
NVP-BYL719; Novartis) receiving approval for the treatment of advanced hormone-receptor
(HR)-positive, HER2-negative breast cancers, in combination with the estrogen receptor (ER)
antagonist fulvestrant [5]. The randomized phase III trial concluded that a clinically-relevant
benefit of the combination therapy was more likely in patients with PIK3CA-mutant tumors
[5]. The FDA approval of alpelisib was accompanied by approval of the companion diagnostic
therascreen PIK3CA test (QIAGEN) which detects 11 PIK3CA hotspot mutations. Despite
these advances, a substantial proportion of patients with PIK3CA-mutant tumors failed to
improve on the combination therapy [5], highlighting the need for further refinement of cur-
rent patient stratification strategies.
Experimental evidence suggests that heterozygous expression of a strongly activating
PIK3CAmutation alone is insufficient to transform cells in vitro or to induce tumorigenesis in
vivo (reviewed in Ref. [6]). This is supported by observations of people with disorders in the
PIK3CA-related overgrowth spectrum (PROS) which is caused by the same PIK3CAmutations
found in cancer, but does not feature discernible excess risk of adult malignancy [6]. It thus
appears that additional events are required for cell transformation, possibly in the PI3K path-
way itself. In this regard, we and others have shown that many PIK3CA-associated cancers har-
bour multiple independent mutations activating the PI3K pathway, including multiple
PIK3CAmutations in cis or trans [3,7–10].
Overexpression of wild-type Pik3ca or the hotspot Pik3caH1047Rmutation has been linked
to dedifferentiation and stemness in murine models of cancer [11–17], particularly of the
breast, but Pik3ca gene dose-dependent regulation was not addressed in these studies. Pluripo-
tent stem cells (PSCs) share key characteristics with cancer cells, including developmental plas-
ticity, the capacity for indefinite self-renewal, rapid proliferation and high glycolytic flux [18].
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We recently reported that human PSCs with two endogenous alleles of the strongly activating
cancer hotspot mutation PIK3CAH1047R exhibit pronounced phenotypic differences compared
to isogenic cells heterozygous for the same PIK3CA variant [8]. These differences include par-
tial loss of epithelial morphology, widespread transcriptional reprogramming and self-sus-
tained stemness in vitro and in vivo, none of which were observed in heterozygous
PIK3CAH1047R cells [8]. Collectively these findings emphasize the importance of PIK3CA
mutation dose, and its inferred functional correlate, PI3K signaling strength, in determining
the cellular consequences of mutational activation of this pathway. In line with this notion,
dose-dependent effects on stemness have also been reported in mouse embryonic stem cells
with heterozygous versus homozygous loss of Pten [19].
Stemness or dedifferentiation, accompanied by re-expression of embryonic genes, is a fea-
ture of aggressive tumors [20,21]. Beyond direct histopathological analyses, this has been sup-
ported by computational analyses examining a tumor’s expression of defined PSC gene
signatures [20–23]. With the continuing collection and curation of multi-omics datasets by the
cancer community, such signatures can now be employed en masse to study how cancer-spe-
cific stemness relates to other biological processes of interest. This can, however, be challeng-
ing for highly dynamic processes such as signaling pathway activity which is best inferred
using temporal protein-based measurements. Such measurements are not available for most
human tissue samples. A complementary approach is the use of transcriptional “footprints” of
pathway activation, derived from the systematic curation of gene expression data obtained
from direct perturbation experiments [24–26]. Given the slower time scale of gene expression
regulation relative to acute signaling changes at the protein level, transcriptional footprint
analyses can be thought of as an integrated measure of pathway activity over a longer time
scale. The power of such analyses has been best demonstrated by The Connectivity Map
Resource, which enables discoveries of gene and drug mechanisms of action on the basis of
common gene-expression signatures [27,28].
Here, we set out to determine whether a signaling strength-dependent PI3K-stemness
link exists in human breast cancer, and to provide a systematic characterization of relevant
clinical and biological correlates. We used established, open-source methods to infer PI3K/
AKT/mTOR (henceforth PI3K signaling) and stemness scores from publicly available tran-
scriptomic data from nearly 3,000 primary human breast tumors. Our analyses reveal a pos-
itive, linear relationship between PI3K signaling and stemness scores, and uncover a
surprising “biphasic” relationship between these scores and mutant PIK3CA allele dosage.
This suggests a potential utility for combined functional genomics and genotype assess-
ments in future patient stratification for PI3K-targeted therapy. Consistent with prior cell
biology studies, breast tumor transcriptomic analyses revealed strong clustering of PI3K/
AKT/mTOR and stemness scores with MYC-related biological processes, including prolif-
eration and glycolysis. With the advent of routine tumor gene expression analyses, further
dissection of the mechanisms driving these associations may enable much-needed further
therapeutic advances.
Results
Transcriptional indices of PI3K signaling activity in breast cancer are
positively associated with stemness and tumor grade
The molecular features of stemness can be captured by gene signatures derived by computa-
tional comparisons of pluripotent stem cells and differentiated derivatives. Among the first
such signatures was PluriNet (n = 299 genes; S1 Table), generated with machine learning
methods [29], and applied below to primary breast cancer samples. To evaluate PI3K pathway
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activity in the same samples, we used the “HALLMARK_PI3K_AKT_MTOR_SIGNALING”
gene signature from the Broad Institute Molecular Signature Database (MSigDB). This gene
signature consists of 105 genes upregulated upon PI3K pathway activation across multiple
studies [25] (S2 Table), thus corresponding to a gene expression footprint of PI3K pathway
activation. Of note, only 4 genes were shared between the PI3K/AKT/mTOR and PluriNet
gene lists, precluding a direct confounding effect on the relationship between stemness and
PI3K signaling scores tested here.
We used Gene Set Variation Analysis (GSVA) [30], an open-source enrichment analysis
method, to calculate stemness and PI3K signaling scores on the basis of these gene expression
signatures, independently in breast cancer tumors with available transcriptomic data from the
METABRIC (n = 1980; used for primary analyses) and TCGA patient cohorts (n = 928; used
for secondary analyses). Similar to the conventional gene set enrichment analysis (GSEA),
GSVA is a non-parametric method that evaluates the concerted behavior of functionally
related genes; in contrast to GSEA, however, the GSVA method is unsupervised and enables
functional enrichment analyses beyond conventional case-control experimental designs [30].
This makes the GSVA method ideally suited for pathway-centric analyses of transcriptomic
data with diverse clinical and phenotypic correlates, conditional upon a relatively large sample
size (n> 30) [30].
Consistently, the GSVA-derived PI3K signaling score in METABRIC breast tumors corre-
lated significantly with the stemness score (Fig 1A; Spearman’s Rho = 0.5, p< 2.2e-16) as well
as tumor grade status (Fig 1B), a measure of tumor dedifferentiation based on histopatholog-
ical assessment. A similar linear relationship between PI3K signaling and stemness scores was
also found in TCGA breast cancers (Fig 1C; Spearman’s Rho = 0.4; p< 2.2e-16).
To ascertain the ability of this approach to capture bona fide features of stemness and PI3K
signaling from transcriptomic data, we next performed pairwise-correlations with indepen-
dently-derived transcriptomic indices for each phenotype. Across both METABRIC (Fig 1D)
and TCGA (Fig 1E) breast tumors, the PluriNet-derived stemness score showed good concor-
dance with alternative stemness scores obtained using the one-class logistic regression
(OCLR)-based signature of Malta et al. [22], or the signature from Miranda et al. [23], a modi-
fied version of a gene set initially developed by Palmer et al. [21]. The strongest correlations
(Spearman’s Rho > 0.7) were between PluriNet and the OCLR-based signature, both of which
were derived using distinct machine learning algorithms.
Next, we evaluated the concordance of our PI3K signaling score with complementary mea-
sures of pathway activity. First, we applied PROGENy to obtain an independent measure of
PI3K pathway activation based on transcriptomic footprints. Instead of the enrichment score
calculated by GSVA, PROGENy uses a linear model to infer pathway activity from the expres-
sion of 100 pathway-responsive genes [24]. The GSVA- and PROGENy-derived PI3K signal-
ing scores exhibited a significant positive correlation across both METABRIC (Spearman’s
Rho = 0.61) and TCGA (Spearman’s Rho = 0.45) breast cancers (Fig 1D and 1E). Similar posi-
tive associations were obtained when we used GSVA to calculate a PI3K signaling score based
on two alternative PI3K-response gene signatures (“PI3K_Jin_1” and “PI3K_Jin_2”), which
were recently shown to associate positively with human breast cancer metastases in the brain
[31]. All these PI3K signaling scores exhibited consistently significant, positive correlations
with the stemness scores tested above (Fig 1D and 1E).
Finally, we sought independent experimental evidence that the “HALLMARK_PI3-
K_AKT_MTOR_SIGNALING” gene signature can be used to identify biologically meaningful
activation/inhibition of the PI3K pathway, as suggested by the methodology used to generate
this transcriptional footprint [25]. To this end, we used untransformed, immortalized human
breast epithelial MCF10A cells with stable PIK3CAH1047R overexpression, alongside the
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Fig 1. Transcriptionally-inferred PI3K pathway activation and breast tumor stemness/grade exhibit significant, positive
association. (A) Rank-based (Spearman’s Rho) correlation analysis of the relationship between transcriptionally-inferred PI3K pathway
activity and stemness scores, evaluated across METABRIC breast cancer transcriptomes. Scores were determined using Gene Set
Variation Analysis (GSVA) with mSigDB “HALLMARK_PI3K_
AKT_MTOR_SIGNALING” (for PI3K activity score) and “MUELLER_PLURINET” (for stemness score) gene signatures [25,29,30].
Gene lists used are included in Supplementary Tables 1 and 2. (B) PI3K signaling and stemness score distributions across breast cancer
grade (METABRIC). ��� p� 0.001 according to one-way ANOVA with Tukey’s Honest Significant Differences method. The global p-
value for each linear model is indicated within each plot. (C) As in (A) but based on TCGA breast invasive carcinoma (BRCA)
transcriptomic data. (D) Rank-based correlation analyses of the stemness (PluriNet-based) and PI3K (mSigDB-based) scores used in the
current study against published and independently-derived transcriptional indices for stemness and PI3K signaling, across METABRIC
breast cancer transcriptomic data. Individual Rho coefficients are shown within the respective circles whose sizes are matched
accordingly. Only significant correlations are shown (family-wise error rate< 0.05). E) As in (D) but based on TCGA BRCA
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respective empty vector (EV) control cells [32]. Assessed in growth factor-replete conditions
to reflect a more physiological environment, PIK3CAH1047R cells exhibited the expected
increase in p110α expression and PI3K/AKT/mTOR1 pathway activation as measured by
phosphorylation of AKT on S473 (pAKT) and T246 on PRAS40 (pPRAS40) (Fig 2A). Treat-
ment of PIK3CAH1047RMCF10A cells with 500 nM of the p110α-selective inhibitor BYL719
(alpelisib/Piqray; Novartis) restored pAKT and pPRAS40 levels to those in control cells, both
after 48 h and 120 h of drug exposure (Fig 2A). Moreover S240/S244 phosphorylation of S6
(pS6)–a marker of mTORC1 activity–in PIK3CAH1047RMCF10As cells treated with BYL719
decreased below those observed in EV control cells (Fig 2A). We next performed bulk mRNA
sequencing of replicate samples in the same conditions, asking if the results from a conven-
tional GSEA with the “HALLMARK_PI3K_AKT_MTOR_SIGNALING” gene set would
reflect the observed biochemical changes. The samples exhibited low intra-group variability
and clustered according to PIK3CAH1047R expression and BYL719 treatment based on unsu-
pervised, principal component analysis (PCA) (Fig 2B). Given possible transcriptional delays,
we analyzed both time points to ensure that we would capture the response to p110α inhibi-
tion. While the observed enrichments for the “HALLMARK_PI3K_AKT_MTOR_SIGNAL-
ING” gene set were modest (Fig 2C), as expected from the biochemical signaling data, the
direction of change across the different comparisons was consistent with our hypothesis–posi-
tive when evaluating MCF10A cells with PIK3CAH1047R overexpression relative to the corre-
sponding EV controls, and negative upon treatment of PIK3CAH1047R -overexpressing cells
with BYL719 (Fig 2C). Similar results were obtained with the related “HALLMARK_M-
TORC1_SIGNALING” gene set (Fig 2C), however upon further testing we found that the rela-
tive shifts for this signature were not robust to differences in background gene expression (S1
Fig). We note that the relative shifts in calculated scores are the basis for all our subsequent
breast cancer analyses in the context of GSVA-based score calculations, as per published exam-
ples [30].
Taken together, these results provide evidence that: 1) pre-defined transcriptional foot-
prints for the PI3K pathway can be used to obtain a biologically meaningful score for pathway
activity from transcriptomic data; 2) there is a positive, “strength”-dependent relationship
between stemness and overall PI3K signaling in human breast cancer.
Stemness and PI3K signaling scores differ across breast cancer subtypes
Using our GSVA-based stemness and PI3K signaling scores, we next sought to determine their
relationship with clinical breast cancer subtype. Upon stratification of METABRIC breast can-
cers into those with “high” and “low” PI3K signaling scores, we found that around 45% of
tumors with a high PI3K signaling score were ER-negative, in contrast to 4% of tumors with
low PI3K signaling scores (Fig 3A). In TCGA, the corresponding percentages were 33% and
7% (S2A Fig). Consistently, PI3K signaling and stemness scores were highest in the more
aggressive PAM50 breast cancer subtypes (Fig 3B), including Basal, HER2 and Luminal B.
These findings are in line with independent studies relying on alternative indices and methods
for quantifying PI3K signaling and stemness in separate analyses [20,22,31,33–35]. Impor-
tantly, the correlation of a high PI3K signaling score with ER-negativity contrasts with the
transcriptomic data. The Stemness_OCLR score is based on a machine-learning-derived stemness signature [22]; the Stemness_Miranda
score is based on a modification of the stemness signature of Palmer et al. [21,23]. The PI3K_Progeny score is based on the analysis of
benchmarked pathway-responsive genes as described in Ref. [24]. The “PI3K_Jin_1” and “PI3K_Jin_2” gene signatures were obtained
from Ref. [31]. Note that the scores calculated using OCLR and PROGENy are independent of the GSVA method used to generate
scores based on the remaining signatures.
https://doi.org/10.1371/journal.pgen.1009876.g001
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Fig 2. Experimental validation of the PI3K signaling score in a breast epithelial cell model with oncogenic PI3Kα activation (PIK3CAH1047R). (A)
Western blotting for canonical class IA PI3K pathway signaling components in MCF10A cells with retroviral overexpression of PIK3CAH1047R -/+ 500 nM
BYL719, compared to empty vector (EV) control cells. Samples were collected after 48 h and 120 h of inhibitor treatment in growth factor-replete medium. All
samples from the same experimental trial were loaded on the same gel, with the stippled white line included to emphasize the different time points. The
quantified data are shown as barplots with the corresponding replicate points. All targets were normalized to a corresponding total protein as indicated on the y
axis, in addition to normalization to the EV_DMSO condition within each experimental trial and time point. The diagram on the right-hand side represents a
simplified schematic of PI3Kα signaling, with stippled arrows for indirect regulation; known negative feedback loops have been omitted for clarity. (B)
Principal component (PC) analysis of transcriptomic data corresponding to samples in (A) except for exclusion of a single EV_DMSO_48 h replicate due to
technical issues with the mRNA library. (C) Gene set enrichment analysis (GSEA) following differential gene expression analysis and gene ranking with respect
to the indicated comparisons (PIK3CAH1047R + DMSO versus EV-control; PIK3CAH1047R + BYL719 versus EV-control) at 48 and 120 h. The analyses were
performed with the “HALLMARK_PI3K_AKT_MTOR_SIGNALING” (105 genes; 90 present in the ranked gene list) and the
“HALLMARK_MTORC1_SIGNALING” (200 genes; 192 present in the ranked gene list) gene sets as indicated (number of overlapping genes between the two
gene sets = 24). The total number of ranked genes was 11,777. The p-values correspond to each enrichment’s significance following 100,000 permutations of
the gene ranks; � p� 0.05, �� p� 0.01, ��� p� 0.001; FDR = 0.05. See also S1 Fig.
https://doi.org/10.1371/journal.pgen.1009876.g002
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known enrichment of PIK3CAmutations in ER-positive breast tumors [35,36], which were
also reproduced by our analyses (Fig 3C and 3D).
PI3K signaling and stemness scores, but not binary PIK3CA mutant status,
predict prognosis in breast cancer
As expected, given the positive association between PI3K signaling and stemness scores with
tumor grade, both scores were negatively associated with patient survival in the METABRIC
cohort, with a clear dosage relationship between the assessed scores and survival, including
progressively worsened survival in tumors with high vs intermediate vs low scores (Fig 4A and
4B). This relationship was not simply driven by the above-mentioned enrichment of high
PI3K signaling and stemness scores in more aggressive ER-negative tumors, as the prognostic
power of both scores remained when evaluated in ER-positive tumors only (Fig 4C and 4D).
In contrast, although overall ER-negative cases with available survival data were limited in
number, we in fact noticed a loss of prognostic power when evaluating the two scores in this
breast cancer subset (S2B and S2C Fig). Due to limited data, extensive survival analyses were
Fig 3. High PI3K signaling and stemness scores, but not PIK3CA mutations, are enriched in aggressive breast cancer subtypes. (A) PI3K signaling score
distribution in METABRIC breast tumors stratified according to ER status. (B) PI3K signaling and stemness score distributions across METABRIC breast
cancers stratified according to PAM50 subtype; �� p� 0.01, ��� p� 0.001 according to Tukey’s Honest Significant Differences method. (C) and (D) The
distribution of PIK3CA wild-type (PIK3CA.WT) and mutant (PIK3CA.MUT) samples in METABRIC breast cancers, stratified according to ER status (C) or
PAM50 subtype (D).
https://doi.org/10.1371/journal.pgen.1009876.g003
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Fig 4. PI3K signaling and stemness scores, but not PIK3CA genotype, are prognostic in ER+ breast cancer. Pan-breast cancer patient survival in
METABRIC, as a function of PI3K signaling (A) or stemness (B) score. Survival analysis in estrogen receptor (ER)-positive breast cancer patients, as a function
of PI3K signaling (C) or stemness (D) score. Low, intermediate and high classifications represent the bottom quartile, the interquartile range and the top
quartile of the respective scores. (E) and (D) represent pan- and ER-positive breast cancer patient (METABRIC) survival, respectively, as a function of binary
PIK3CA genotype. The mutant genotype captures only cases with activating missense mutations. The sample size for each panel and subgroup is indicated, and
p-values were calculated using a log-rank test. The 95% confidence intervals are indicated by shading.
https://doi.org/10.1371/journal.pgen.1009876.g004
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not possible in TCGA breast cancers, however the negative association between PI3K signaling
“strength” and pan-breast cancer survival was reproduced (S2D Fig).
As previously reported [36–38], PIK3CAmutant status (hotspot and non-hotspot) had no
prognostic power in pan-breast or ER-positive METABRIC tumors, despite their enrichment
in the ER-positive cohort (Fig 4E and 4F). Interestingly, however, the presence of PIK3CA
mutations in ER-negative tumors appeared to be associated with worse prognosis (S2E Fig).
Stratification of breast cancers by mutant PIK3CA allele dosage reveals a
biphasic relationship with PI3K signaling and stemness scores
Given the divergent correlations between PI3K signaling scores and PIK3CAmutant status in
the survival analyses, we next assessed the relationship between stemness/PI3K signaling
scores and PIK3CA genotype, taking into account available information on mutant PIK3CA
allele dosage on the basis of our previous work with TCGA tumors [8]. For METABRIC, we
inferred PIK3CA copy number changes based on available information on allele gain/amplifi-
cation in cBioPortal. For both cohorts, we specifically focused on tumors harboring one or
more hotspot PIK3CA alleles, given the well-established increased cellular activity of these
mutants and their association with disease severity [39–42].
As PI3K pathway activation and tumor dedifferentiation can be triggered by a range of onco-
genic hits, the relatively high PI3K signaling and stemness scores in breast cancers with wild-type
PIK3CAwere not entirely surprising (Fig 5A and 5B). It was, however, counterintuitive that the
presence of a single oncogenic PIK3CAmissense variant was associated with a substantial reduc-
tion in the stemness score and a modest reduction in the PI3K score (Fig 5A and 5B). Relative to
tumors with a single PIK3CAmutant copy, those with multiple oncogenic PIK3CA copies exhib-
ited higher PI3K signaling and stemness scores (Fig 5A and 5B). This relationship was lost upon
simple binary classification based on PIK3CA genotypes (i.e. wild-type vsmutant) (Fig 5A and
5B). The observed biphasic relationship also remained upon stratification of tumors according to
genome doubling (data only available for TCGA samples; Fig 5C).
Surprised by this observation, we next asked whether the biphasic relationship between
PIK3CA genotype and transcriptionally-derived PI3K signaling/stemness scores could be recapit-
ulated in a controlled cellular model. We turned to human induced pluripotent stem cells (iPSCs)
that we engineered previously to harbor heterozygous or homozygous PIK3CAH1047R alleles, the
only reported cellular models of heterozygous and homozygous PIK3CAH1047R expression on an
isogenic background to date [43]. Using the published high-depth transcriptomic data on PIK3-
CAWT/H1047R and PIK3CAH1047R/H1047R iPSCs [43], we next performed GSEA with the two gene
set signatures used for PI3K signaling and stemness score calculations in the breast cancer setting
(MSigDB “HALLMARK_PI3K_AKT_MTOR_SIGNALING” and PluriNet, respectively). In line
with their established biochemical and cellular phenotypes [8,43], homozygous PIK3CAH1047R
iPSCs showed strong positive enrichment for both PI3K/AKT/mTOR and stemness gene signa-
tures (Fig 5D). In contrast, their heterozygous PIK3CAH1047R counterparts presented with a
strong negative enrichment for stemness, and a negative albeit statistically insignificant enrich-
ment for the transcriptional PI3K/AKT/mTOR signature (Fig 5D). These patterns mirror those
observed in human breast cancers and corroborate the existence of a previously unappreciated
biphasic relationship between PIK3CA allele dosage and stemness.
Breast cancer PI3K signaling and stemness scores are positively associated
with proliferative and metabolic processes
Given the high depth and large sample size of the available breast cancer transcriptomic data,
we next undertook a global analysis encompassing all 50 “hallmark” MSigDB gene sets and the
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PluriNet signature to identify relevant biological processes associated with breast cancer stem-
ness and a high PI3K signaling score. Such processes can be used to guide future experimental
studies aimed at dissecting the molecular underpinnings of the observed relationships. To
identify such associations, we applied GSVA to METABRIC and TCGA data to generate a
score for each gene signature, followed by correlation analysis with hierarchical clustering.
This global approach also allowed us to confirm that we are able to identify biologically-rele-
vant gene signature clusters more broadly. For example, gene signatures associated with
inflammatory processes clustered together according to strong pairwise positive correlations
in both METABRIC and TCGA datasets (Fig 6 bottom cluster, Fig 7 top left cluster).
Data from either breast cancer cohort revealed a characteristic clustering pattern for PI3K
signaling and stemness scores, including strong positive associations with proliferative (e.g.,
“G2M_checkpoint”, “E2F_targets”, “MYC_targets”) and metabolic (e.g., “Glycolysis”, “Oxida-
tive_phosphorylation”, “Reactive_oxygen_species”) gene signatures (Figs 6 and 7). These sig-
natures shared few genes (S2F Fig), ruling out technical artefacts as a source of the positive
associations. Given prior observations of a strong correlation between PluriNet and cell cycle
signatures, it has been suggested that PluriNet genes function as a distinct module within a
larger context including cell cycle-specific genes [29]. Notably, the separate mTORC1 gene
Fig 5. The presence of a single-copy, but not multi-copy, hotspot PIK3CA mutation is associated with lower PI3K signaling and stemness score. (A) PI3K
signaling and stemness score distributions across TCGA breast cancers following stratification according to the presence or absence of single vsmultiple copies
of PIK3CA “hotspot” variants (C420R, E542K, E545K, H1047L, H1047R); �� p� 0.01, ��� p� 0.001 according to one-way ANOVA with Tukey’s Honest
Significant Differences method. (B) As in (A) but performed using METABRIC breast cancer transcriptomic and genomic data. (C) As in (A) but further
stratified according to available genome doubling information. The shown statistics apply to both subpanels and are the result of a two-way ANOVA, followed
by Tukey’s Honest Significant Differences method to determine differences between the indicated PIK3CA genotypes following adjustment for genome
doubling. (D) Complementary GSEA-based PI3K signaling and stemness score calculations using publicly-available transcriptomic data from iPSCs with
heterozygous or homozygous PIK3CAH1047R expression [43]; enrichments are calculated relative to isogenic wild-type controls. �� p� 0.01, ��� p� 0.001 for
individual enrichments, according to FDR = 0.05 (Benjamini-Hochberg correction for multiple comparisons).
https://doi.org/10.1371/journal.pgen.1009876.g005
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signature exhibited a much stronger correlation (Spearman’s rho = 0.7) with the stemness
score compared with the PI3K_AKT_mTOR signature used to derive the PI3K signaling
score, on par with the correlation values observed between PluriNet and cell cycle signatures.
Discussion
This study provides a comprehensive analysis of the relationship between PI3K signaling and
stemness (or tumor dedifferentiation) using two large breast cancer transcriptomic datasets
encompassing almost 3,000 primary tumors. We demonstrate a strong, positive relationship
between transcriptionally-inferred PI3K signaling strength, stemness gene expression and his-
topathological tumor dedifferentiation. Importantly, we show that stratification of breast
tumors according to single vsmultiple copies of PIK3CA hotspot mutations results in distinct
and near-opposite distributions with respect to PI3K signaling and stemness scores, an obser-
vation that was recapitulated in a controlled cell model system.
The PI3Kα-specific inhibitor alpelisib (Piqray/NVP-BYL719; Novartis) recently received
approval for use in combination with the ER-antagonist fulvestrant in the treatment of ER-
Fig 6. Breast cancer (METABRIC cohort) PI3K signaling and stemness scores form a common cluster with
proliferative and metabolic processes. Rank-based correlation analyses across METABRIC GSVA-derived gene set
enrichment scores, evaluating all 50 mSigDB Hallmark Gene Sets and PluriNet. Individual Rho coefficients are shown
within the respective circles whose sizes are matched accordingly. Only significant correlations are shown (family-wise
error rate< 0.05). The clusters were generated using unsupervised hierarchical clustering. The positions of PluriNet
(stemness) and PI3K_AKT_MTOR (PI3K signaling) signatures are highlighted in red.
https://doi.org/10.1371/journal.pgen.1009876.g006
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positive breast cancers. The benefit of this treatment was most notable in PIK3CA-mutant
tumors, yet the predictive value of binary mutant classification was incomplete [5]. This is a
common observation for single gene biomarkers in cancer and has long spurred discussions
about the utility of phenotypic pathway signatures for clinical response prediction [44]. It is
therefore interesting to note that while PIK3CAmutations are enriched in the ER-positive
breast cancer subgroup, on average these tumors also feature lower PI3K signaling and stem-
ness scores as inferred from our transcriptional footprint analyses. The opposite is true for ER-
negative tumors. Given that the MSigDB “HALLMARK_PI3K_AKT_mTOR_SIGNALING”
signature used in our study also encompasses mTORC1-related processes, in line with a strong
correlation with the separate hallmark mTORC1 signature, our findings support a previous
study reporting a negative relationship between the presence of a PIK3CAmutation and
mTORC1 signaling in ER-positive/HER2-negative breast cancers [38]. As we show, however,
simple binary classification of tumors into PIK3CA wild-type and mutant genotypes, without
allele dosage considerations, is likely to have masked a more complex relationship. Conversely,
our study does not distinguish between AKT- and mTORC1-specific processes, which may
nevertheless be important to consider for further mechanistic understanding and patient strat-
ification [38,45,46]. Given the high correlation between the hallmark “PI3K_AKT_mTOR_-
SIGNALING” and “mTORC1_SIGNALING” signature scores (Spearman’s rho = 0.7), we
Fig 7. Breast cancer (TCGA cohort) PI3K signaling and stemness scores form a common cluster with proliferative
and metabolic processes. As in Fig 6 except based on data from the TCGA breast cancer cohort as indicated.
https://doi.org/10.1371/journal.pgen.1009876.g007
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speculate that the observed relationship between PI3K and stemness in breast cancer may be
driven by mTORC1-dependent processes.
Disentangling the apparent biphasic relationship between single versusmultiple copies of
PIK3CAmutation and stemness scores will require direct experimentation, but is likely to
reflect context-dependent feedback loops within the intracellular signaling networks. Such
feedback loops can result in non-intuitive and discontinuous outcomes upon different levels of
activation of the same pathway, as demonstrated in our isogenic iPSC system with heterozy-
gous and homozygous PIK3CAH1047R expression [8,43]. In general, our observations caution
against the use of a binary PIK3CA-mutant-centric approach to predict PI3K pathway activity
outcomes. Moreover, we note that numerous alternative (epi)genetic changes–including
PIK3CA amplification or increased mutant-specific mRNA expression, loss of PTEN or
INPP4B –may converge on increased, and perhaps dose-dependent, PI3K pathway activation
[3,33,35,47,48]. Importantly, such PIK3CAmutant-independent and/or non-genetic mecha-
nism of PI3K pathway activation will be captured by the transcriptional footprint-based PI3K
signaling scores used in our study and will thus contribute to the values observed in non-
PIK3CAmutant tumors. More generally, the diagnostic and therapeutic benefits of combined,
comprehensive genomic and non-genomic analyses were recently demonstrated in patients
with rare cancers [49], and are worth considering in the context of breast and other cancers
where PI3K pathway alterations feature prominently [3].
While PI3K signaling and stemness scores exhibited a strength-dependent negative associa-
tion with patient survival pan-breast cancer as well as in ER-positive tumors, this prognostic
power was not observed with binary genotype-based PIK3CA classification. Paradoxically,
however, PIK3CAmutations had prognostic power in ER-negative tumors, in contrast to PI3K
signaling and stemness scores. This raises the question whether subgroups defined by differ-
ences in PIK3CAmutant status and PI3K signaling/stemness scores differ in their response to
PI3Kα-targeted therapy. PI3K/AKT inhibitors have so far had limited success in TNBC [50–
53], the tumor subgroup with some of the highest PI3K signaling and stemness scores. In the
context of our findings, it is interesting to note that studies in mouse models of metastatic
breast cancer has demonstrated the potential utility of combining PI3K and BET inhibitors to
overcome a MYC-dependent feedback mechanism that limits the benefit of single-agent PI3K
pathway inhibition in this context [54].
It is also notable that our correlation analyses of breast cancer transcriptomes identified a
PI3K/stemness cluster encompassing key processes associated with the MYC regulatory mod-
ule in pluripotent stem cells [55]; a module previously shown to be active in various cancers
and predictive of cancer outcome [56]. Moreover, computational analyses of iPSCs with
homozygous PIK3CAH1047R expression identified MYC as a central hub connecting the PI3K,
TGFβ and pluripotency networks in these cells [43]. Recently, PIK3CAH1047R/KRASG12V dou-
ble knock-in breast epithelial cells were also shown to exhibit a high MYC transcriptional sig-
nature, when compared to single-mutant counterparts [57]. Collectively, the recurrent
appearance of MYC in these independent analyses raises the possibility that this transcription
factor governs the mechanistic link between stemness and PI3K signaling strength in pluripo-
tent stem cells and breast cancer. Experimental studies will be required to test this hypothesis,
alongside a potential involvement of mTORC1 as suggested by the observed strong positive
correlation between the mTORC1 signature and stemness/MYC signatures.
A limitation of the current and previous bulk-tissue transcriptomic analyses is that they
cannot determine (1) whether the observed correlations reflect mechanistic links or spurious
associations caused by a confounder variable that influences two or more processes indepen-
dently and (2) to what extent the observed transcriptomic scores are driven by changes in
tumor subcellular composition, tumor cell type-specific phenotypic alterations, and/or non-
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cell-autonomous interactions with the stroma. Nevertheless, given the ability to reproduce key
observations in controlled cell model systems, our analyses of the relationship between PI3K
signaling dose and stemness in breast cancer may prove useful in guiding future experimental
studies aimed at identifying the exact molecular underpinnings. Since we know that heterozy-
gous PIK3CAH1047R iPSCs exhibit moderate PI3K pathway activation at the biochemical level
[8,43], the fact that this is not captured in a positive transcriptional footprint-based PI3K sig-
naling score in this context is worth noting. Combined with the observation of an apparent
decrease in the PI3K signaling score in tumors with a single copy of a hotspot PIK3CAmuta-
tion, we surmise that this may reflect feedback mechanisms that are sufficient to limit the
influence of intermediate but not strong PI3K pathway activation in certain settings. This war-
rants further studies as it may have important consequences for targeting of tumors with a
high versus low transcriptionally-inferred PI3K signaling score. It is also worth noting that pre-
vious protein-based signaling studies of breast cancer cell lines and tumors with and without
PIK3CAmutations found that PIK3CAmutations were associated with lower and/or inconsis-
tent PI3K pathway activation [33,36,38]. This also emphasizes the need for future benchmark
studies that establish the relationship between the absolute magnitude of individual transcrip-
tomic scores for the PI3K pathway and corresponding biochemical activity, and how this rela-
tionship may be affected by crosstalk with other pathways that converge on similar
transcriptional outputs.
Finally, based on the presented analyses, it will be of interest to evaluate the predictive
power of a combined assessment of PIK3CA genotype and phenotypic PI3K/stemness scores
in patient stratification for clinical trials with PI3K pathway inhibitors and, given the well-
established implication of PI3K signaling in therapeutic response and resistance, with other
cancer therapies.
Materials and methods
METABRIC and TCGA data access and pre-processing
Normalised microarray-based gene expression for METABRIC breast tumor samples were
obtained from Curtis et al. [58], and clinical data from Rueda et al. [59]. The relevant METAB-
RIC mutation data were downloaded from cBioPortal in January (mutation-only) and March
(mutation and copy number) 2020 [60]. TCGA breast invasive carcinoma (BRCA) RNAseq,
mutational and clinical data were retrieved from the GDC server (legacy database) using the
TCGAbiolinks package [61], with additional mutation data retrieved from cBioPortal in Janu-
ary 2021 (for exact details, see the OSF-deposited RNotebooks). The TCGAbiolinks package
was also used for subsequent quantile filtering (quantile value = 0.4; chosen empirically based
on the observed count distributions) of lowly-expressed genes and removal of tumor samples
with low purity (cpe = 0.6). The resulting raw RSEM counts were normalized with the TMM
method [62] and log2-transformed using the voom() function in the limma package prior to
downstream use in GSVA computations.
To analyze the relationships between PIK3CA genotype and PI3K/stemness scores, PIK3CA
mutant datasets were subset for focus on hotspot PIK3CA variants only (C420R, E542K,
E545K, H1047L, H1047R), excluding samples containing both a hotspot and a non-hotspot
variant. The classification of hotspot vs non-hotspot variants was based on known clinical sig-
nificance and frequency in patients with overgrowth caused by a single activating PIK3CA
mutations [41]. Mutation data underwent manual checks to exclude samples with ambiguous
genotype calls as well as all silent mutations.
We obtained information regarding allele amplification/gain in METABRIC breast tumors
from cBioPortal and in TCGA breast tumors from our previous copy number analyses [8]. In
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both cases, such information relies on a well-established computational deconvolution method
known as ASCAT (allele-specific copy number analysis of tumors), which seeks to assign accu-
rate allelic copy number to individual genomic regions while also estimating and adjusting for
both tumor ploidy and normal cell admixture [63].
It remains difficult to ascertain that two or more mutations are present in the same cell as
opposed to different cells. We note, however, that we have focused exclusively on hotspot
PIK3CA variants for ‘allele dosage’ analyses, and such variants have been estimated to be clonal
in breast cancer [64]. This strengthens the notion that our analyses are unlikely to be con-
founded by tumor mosaicism for different PIK3CAmutations.
Calculation of transcription-based signature scores
The “HALLMARK_PI3K_AKT_MTOR_SIGNALING” and PluriNet gene sets were retrieved
from The Molecular Signature Database (MSigDB) using themSigDBr package [65]. Note that
the “HALLMARK_PI3K_AKT_MTOR_SIGNALING” gene set also includes mTORC1-de-
pendent gene expression changes, in contrast to other studies which have sought to separate
AKT- and mTORC1-driven gene expression changes [45,46]. Categorization of scores into
“low”, “intermediate” and “high” was based on the 0.25 quantile, the interquartile range, and
the 0.75 quantile, respectively. The stemness signature used by Miranda et al. [23] was
retrieved from the accompanying supplementary material. The “PI3K_Jin_1” and “PI3K_
Jin_2” gene signatures were obtained from Ref. [31]. Individual scores for each of these signa-
tures were computed with the GSVA package, using the default Gaussian kernel and ESdiff
enrichment values as output [30].
The PROGENy package was used to obtain a PI3K score according to a linear model based
on pathway-responsive genes as described in Ref. [24].
The TCGAnalyze_Stemness() function in TCGAbiolinks was used to calculate a stemness
score according to the machine learning model-based mRNAsi signature reported by Malta
et al. [22].
MCF10A breast epithelial cell culture
The generation of polyclonal non-transformed, immortalized breast epithelial MCF10A cells
stably engineered to overexpress either empty vector (EV) or bovine hemagglutinin-tagged
PIK3CAH1047R (retroviral vector: pJP1520-HA-PIK3CA(H1047R)) was described previously
(see Supplementary Material of Ref. [32]). Cells were maintained in DMEM/F12 supplemented
with the components indicated in Table 1 and subcultured with Trypsin-EDTA (Fisher Scien-
tific #MT-25-053-CI) at subconfluence. Cells were subcultured for two weeks post-thawing to
ensure adaptation and used for experiments at passage 6–7. All treatments were performed
according to a backwards design for simultaneous collection of all samples within a replicate
run. Briefly, cells were seeded at 1500 cells/cm2 (14000 cells per 6-well) on day 1, followed by
Table 1. Culture medium composition for MCF10A breast epithelial cells.
Reagent Vendor Catalogue no. Final concentration
Horse Serum Gemini Bio 100501 5% (v/v)
Gibco Recombinant AOF Insulin Life Technologies A11382II 10 μg/ml
Hydrocortisone Sigma H4001 0.5 mg/ml
Recombinant hEGF R&D Systems 236-EG-01MAF-100-15 20 ng/ml final
Cholera toxin List Biological Lab 100B 100 ng/ml final
DMEM/Ham’s F12, with L-glutamine, phenol red, and sodium pyruvate Wisent Bioproducts 319-075-CL 500 ml
https://doi.org/10.1371/journal.pgen.1009876.t001
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start of the 120 h DMSO or BYL719 (500 nM; Active Biochem #A-1214) on day 2, including
full medium replacement for all cultures. Media replacement -/+ treatments was repeated on
day 3 and 5. On day 5, 48 h treatments with DMSO or BYL719 were also initiated. On day 7,
cells were washed once with 2 ml ice-cold PBS, followed by snap-freezing on dry ice and stor-
age at -80˚C until further processing. All media replacements and the final collection were per-
formed at the same time of day to minimize biological noise.
Western blotting
Cells were lysed in RIPA buffer (150 mM Tris-HCl, 150 mM NaCl, 0.5% (w/v) sodium
deoxycholate, 1% (v/v) NP-40, pH 7.5) containing 0.1% (w/v) sodium dodecyl sulfate, 1
mM sodium pyrophosphate, 20 mM sodium fluoride, 50 nM calyculin, and 0.5% (v/v)
protease inhibitor cocktail (Sigma-Aldrich) for 15 min. Cell extracts were precleared by
centrifugation at 14,000 rpm for 10 minutes at 4˚C. The Bio-Rad DC protein assay was
used to assess protein concentration, and sample concentration was normalized using
SDS sample buffer (62.5mM Tris pH 6.8, 2% SDS, 10% Glycerol, Bromophenol Blue) sup-
plemented with 5% 2-mercaptoethanol (Sigma Aldrich #M3148-100ML) immediately
before use. Lysates were resolved on acrylamide gels by SDS-polyacrylamide gel electro-
phoresis with PageRuler Plus pre-stained protein ladder (Fischer Scientific # PI26619) to
approximate the size of separated proteins, then electrophoretically transferred to nitro-
cellulose membrane (BioRad) at 100 V for 90 min. Membranes were blocked in 5% (w/v)
bovine serum albumin (Boston Bioproducts #P-753) in tris-buffered saline (TBS) for 1 h
then incubated with specific primary antibodies diluted in 5% (w/v) bovine serum albu-
min in TBS-T (TBS with 0.05% Tween-20) at 4˚C overnight, shaking. The next day, mem-
branes were washed with TBS-T then incubated for 1 h at room temperature with
fluorophore-conjugated secondary antibodies (LI-COR Biosciences). Details for all anti-
bodies are provided in Table 2. The membrane was washed again with TBS-T then imaged
with a LI-COR Odyssey CLx Imaging System (LI-COR Biosciences). Subsequent quantifi-
cations were performed in FIJI/ImageJ, by drawing a rectangle of the same size around
each band of interest, as well as above it for background subtraction. The mean grey value
was recorded and subtracted from 256, followed by subtraction of the background signal
from the corresponding band signal. All targets were normalized to a corresponding total
protein as indicated in the figure, in addition to normalization to the EV_DMSO condi-
tion within each experimental replicate and time point. All raw blot images and quantifi-
cations are deposited on the Open Science Framework and can be accessed via the
following link: https://osf.io/dexgq/.
Table 2. Primary and secondary antibodies used for Western blotting. CST, Cell Signaling Technology. mAb, monoclonal antibody.
Primary antibody (clone if mAb) Vendor Catalogue # Lot # Species Size (kDa) Dilution
p110α (C73F8) CST 4249 7 rabbit 110 1:1000
pAKT S473 (D9E) CST 4060 24 rabbit 60 1:1000
AKT (C67E7) CST 4691 20 rabbit 60 1:1000
pPRAS40 T246 (C77D7) CST 2997 12 rabbit 40 1:1000
PRAS40 (D23C7) CST 2691 11 rabbit 40 1:1000
pS6 S240/S244 (D68F8) CST 5364 7 rabbit 32 1:1000
S6 (5G10) CST 2217 9 rabbit 32 1:1000
Vinculin (E1E9V) CST 13901 6 rabbit 124 1:1000
Secondary antibody
IRDye 800CW Goat anti-Rabbit IgG (H + L) LI-COR 926–32211 D00825-14 goat 1:20,000
https://doi.org/10.1371/journal.pgen.1009876.t002
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MCF10A RNA sequencing and data analyses
Snap-frozen cells were thawed on ice and processed for RNA extraction with Takara’s
Nucleospin RNA Plus (#740984.50) according to the manufacturer’s instructions. Samples
were submitted to Novogene for quality control (Agilent 2100 analysis), mRNA library
preparation (unstranded) and final paired-end sequencing on an Illumina NovaSeqS4
lane.
Raw read processing was performed with the Nextflow (version 20.07.1) nf-core RNAseq
pipeline (version 1.4.2) [67], with Spliced Transcripts Aligment to a Reference (STAR) [68] for
read alignment to the human genome (Homo_sapiens.GRCh38.96.gtf) and featureCounts [69]
for counting of mapped reads (multimapped reads were discarded). Subsequent data process-
ing was performed in R according to the limma-voom method [70]. Briefly, raw counts were
converted to counts per million (cpm) using the cpm() function in the edgeR package [71], fol-
lowed filtering of lowly expressed genes using the TCGAbiolinks package with quantile values
0.80 (chosen empirically based on the observed count distribution); results using more strin-
gent and more lenient filtering options are also included in S1 Fig. Next, read count normaliza-
tion was performed with the trimmed mean of M (TMM) method [62]. One sample was
removed due to a low total read count and outlier behavior upon unsupervised dimensionality
reduction (principal component analysis with the PCAtools package). The mean-variance rela-
tionship was modelled with voom(), followed by linear modelling and computation of moder-
ated t-statistics using the lmFit() and eBayes() functions in the limma package [70].
Experimental replicate was included as a batch effect term in the model. The associated p-val-
ues for assessment of differential gene expression were adjusted for multiple comparisons with
the Benjamini-Hochberg method at false-discovery rate (FDR) = 0.05 [72].
Gene set enrichment analysis (GSEA)
GSEA on MCF10A and iPSC transcriptomic data was performed in R, on the list of all genes
ranked according to the t statistic for each comparison of interest; the choice of t statistic
ensures that the gene ranking considers signal (fold change) as well as noise. The iPSC gene
lists were obtained from Ref. [43]. Normalized enrichment values and associated p-values
were calculated using fgsea with 100,000 permutation (nperm = 100000) [73]. The normalized
enrichment score computed by fgsea corresponds to the enrichment score normalized to mean
enrichment of random samples, using the same gene set size. Note that GSEA was used instead
of GSVA for these analyses as the latter is recommended for use with relatively large sample
sizes (n> 30) and experimental designs beyond conventional case-control set-ups [30].
Whereas GSEA based on t value rankings evaluates the concerted differential expression of a
set of genes relative to all other genes within a given phenotypic comparison (“supervised”),
the GSVA method evaluates the absolute expression of a set of genes relative to all other genes
and does not require a priori phenotypic comparisons to be specified. Both methods are classi-
fied as competitive since the enrichment score in each case is calculated as a function of gene
expression inside and outside a given gene set. It is important to note that statistical signifi-
cance and absolute scores for individual GSEA enrichment scores can be highly dependent on
prior gene filtering choices as shown in S1 Fig and covered in detail in Ref. [74].
Statistical analyses
Linear models were used to assess the significance of the relationship between stemness and
PI3K scores in both METABRIC and TCGA breast cancer cohorts. One-way ANOVA fol-
lowed by Tukey’s Honest Significant Differences (HSD) method was used to perform pairwise
significance testing with multiple comparison adjustments (adjusted p-value < 0.05) when
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evaluating grade- and cancer subtype-specific differences in PI3K/stemness scores across the
METABRIC cohort; similar analyses were not performed with the TCGA breast cancer data
due to smaller sample size and incomplete grading information. ANOVA with Tukey’s HSD
was also used to evaluate the significance of the relationships between PIK3CA genotype and
PI3K/stemness scores across both cohorts. For linear models as well as ANOVAs, the residuals
were examined to confirm that model assumptions were met. The only assumption that was
violated was that of normality; however, given the large sample size, this violation is expected
to have a minimal impact on model validity [75].
Differences in categorial PI3K/stemness score (“low”, “intermediate”, “high”) distributions
across tumor subtypes and/or genotypes were assessed using a Chi-squared goodness-of-fit
test. The relationship between PI3K/scores and survival was assessed using a non-parametric
log-rank test.
Pairwise correlation analyses and hierarchical clustering of signature scores were performed
using Spearman’s rank correlation and the Ward.D2 method (available through R package
corrplot; https://github.com/taiyun/corrplot). The associated p-values were adjusted for multi-
ple comparisons using the Bonferroni method (family-wise error rate < 0.05).
Statistical analyses pertaining to MCF10A RNA sequencing and GSEA are described in the
relevant sections above.
R packages information
As indicated in the accompanying scripts, all relevant packages were sourced either from
CRAN or Bioconductor (via BiocManager [76]). Figures were produced using the ggplot2
package [77].
Supporting information
S1 Fig. The effect of background gene filtering on the GSEA output. Each plot corresponds
to replicate analyses of the MCF10A transcriptomic data in Fig 2 (main manuscript), following
different filtering thresholds for absolute gene expression. The total number of ranked genes
and their overlap with the tested signatures are shown above each analysis. The p-values corre-
spond to each enrichment’s significance following 100,000 permutations of the gene ranks; �
p� 0.05, �� p� 0.01, ��� p� 0.001; FDR = 0.05.
(TIFF)
S2 Fig. (A) PI3K signaling score distribution in TCGA breast tumors stratified according to
ER status. Survival analysis in estrogen receptor (ER)-negative breast cancer patients, as a
function of PI3K signaling (B) or stemness (C) score. (D) Pan-breast cancer patient survival in
TCGA, as a function of PI3K activity score. (E) ER-negative breast cancer patient (METAB-
RIC) survival as a function of binary PIK3CA genotype. The sample size for each panel and
subgroup is indicated, and p-values were calculated using a log-rank test; where shown, the
95% confidence intervals are indicated by shading. (F) UpSet plot showing intersection set
sizes across the specified gene set combinations.
(TIFF)
S1 Table. mSigDB “HALLMARK_PI3K_AKT_MTOR_SIGNALING” gene list.
(CSV)
S2 Table. mSigDB “MUELLER_PLURINET” gene list.
(CSV)
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33. López-Knowles E. et al. (2010) PI3K pathway activation in breast cancer is associated with the basal-
like phenotype and cancer-specific mortality. Int. J. Cancer 126, 1121–1131. https://doi.org/10.1002/ijc.
24831 PMID: 19685490
34. Creighton C. J. et al. (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K path-
way and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 12.
https://doi.org/10.1186/bcr2594 PMID: 20569503
35. Koboldt D. C. et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490,
61–70. https://doi.org/10.1038/nature11412 PMID: 23000897
36. Stemke-Hale K. et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and
AKT mutations in breast cancer. Cancer Res. 68, 6084–6091. https://doi.org/10.1158/0008-5472.CAN-
07-6854 PMID: 18676830
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